CEP57

Across TCGA pan-cancer cohorts, CEP57 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CEP57 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CEP57 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP57 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CEP57 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.807	0.407	<.001	48	view →
PDAC	DFS	Quartile	All	0.619	0.306	.003	44	view →
LUAD	DFS	Tertile	All	0.803	0.358	<.001	32	view →
UCEC	OS	Tertile	II,III,IV	0.529	1.000	.024	8	view →
HNSC	DFS	Median	All	0.410	1.000	.024	8	view →
GBM	DFS	Quartile	All	0.891	0.693	.016	1	view →
LSCC	DFS	Median	II,III,IV	0.675	0.871	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CEP57–CCRCC (DFS)

Open the CCRCC breakdown →